Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
84 Results Found
Report finds launch prices for new drugs are significantly higher, exceed inflation
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released Oct. 23 by the Institute for Clinical and Economic Review.
3 Ways Pharma Could Jolt Health Care in 2023
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.
Administration announces agreement with Pfizer to lower drug costs
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by other developed nations — wh
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
HHS announces access to real-time drug pricing, changes to prior authorization
The Department of Health and Human Services today announced prescription drug reforms
White House announces steps for drug manufacturers to meet ‘most favored nation’ pricing
The Trump administration today
HHS announces new 340B Rebate Model Pilot Program
The Department of Health and Human Services today issued a
Commerce Department to investigate imports of pharmaceuticals, semiconductors
The Department of Commerce yesterday released notices announcing national security investigations on imports of
AHA Urges Administration to Grant Exceptions for Tariffs for Medications and Medical Supplies
The AHA asks President Trump to consider granting exceptions to the current and proposed tariffs for medical devices and pharmaceuticals made in Mexico, Canada and China that are essential to the provision of safe, effective care in America's hospitals, clinics, and other settings.